Addressing unmet needs in pancreatic cancer with Pascal Hammel


At the American Society of Clinical Oncology Annual Meeting (ASCO; May 31–June 4, Chicago, IL, USA) our Senior Editor, Jade Parker, spoke with Pascal Hammel from Hopital Beaujon (Clichy, France) about how we should be approaching the treatment of pancreatic cancer, his thoughts on neo-adjuvant versus adjuvant treatment for resectable pancreatic cancer and the TRYBECA1 study.

This content is supported by Erytech Pharma.